GlassScriptPhysician profile
Layne Hartnell
NPI 1548906209
$13,285.90
in general payments reported to CMS, 2019-2025
27 companies · $4,075 in 2025
The $4,075 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $336 · 2023: $4,200 · 2024: $4,674 · 2025: $4,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $1,169 · Education: $91.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,689.71 |
| Travel and Lodging | $1,168.57 |
| Education | $91.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,053.79 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $1,795.09 | 2023-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,145.16 | 2022-2025 | Caplyta |
| Alkermes, INC. | $895.53 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $748.11 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $733.20 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $584.01 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $503.78 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $454.90 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $319.52 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $314.72 | 2024-2025 | Cobenfy |
| Lilly USA, LLC | $256.06 | 2022-2024 | Amyvid |
| Collegium Pharmaceutical, INC. | $238.70 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $234.60 | 2023-2024 | Quviviq |
| Lundbeck LLC | $166.54 | 2023-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $164.43 | 2023-2025 | Trintellix |
| Noven Therapeutics, LLC | $101.80 | 2024-2025 | Xelstrym |
| Livanova USA, INC. | $87.29 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Neos Therapeutics, LP | $83.53 | 2022-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Tris Pharma INC | $76.06 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $73.35 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $71.51 | 2023-2025 | Loreev Xr |
| Uswm, LLC | $62.56 | 2023 | Zimhi, Lucemyra |
| Ironshore Pharmaceuticals INC. | $45.75 | 2024 | |
| Avion Pharmaceuticals | $33.01 | 2023 | Methylphenidate Hydrochloride |
| Brainsway USA INC | $29.60 | 2023 | |
| Vertical Pharmaceuticals, LLC | $13.30 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Hartnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.